Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co. could benefit from a recent New England Journal of Medicine report that Avandia, GlaxoSmithKline’s diabetes drug, might heighten the risk of heart attacks by 43 percent, according to Forbes.
Lilly and a Japanese partner have developed Actos, which is similar to Avandia. However, unlike GlaxoSmithKline’s drug, Actos doesn’t make a big difference in cholesterol levels.
Please enable JavaScript to view this content.